News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

LifeSci Advisors Initiates Coverage Of Transition Therapeutics Inc. (TTH.TO)


5/9/2014 9:00:40 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, NY--(Marketwired - May 08, 2014) - LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Transition Therapeutics, Inc. (NASDAQ: TTHI), a biopharmaceutical company that develops novel therapeutics for disease indications in large markets. The Company has a unique business model whereby promising development projects are in-licensed from large pharmaceutical companies, developed through proof-of-concept, and then transitioned back to the pharmaceutical company for late-stage development. For example, Eli Lilly exercised its option in 2013 to reacquire GLP-1 dual agonist TT401, and Transition received a $7 million payment, is entitled to receive milestone payments and double-digit royalties. The Company is currently focused on ELND005, a fully owned asset in Phase II trials for the treatment of agitation and aggression in Alzheimer's disease (AD) and as a therapy for Down syndrome.

"Transition has proven their ability to extract value from early-stage drug candidates by demonstrating proof-of-concept with Eli Lilly's GLP-1 dual agonist candidate and successfully transitioning the asset back to Eli Lilly," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "The recent acquisition of full rights to ELND005 gives the Company a promising late stage clinical asset."

Transition is conducting two Phase II clinical trials with lead candidate ELND005, which was acquired from Perrigo (formerly Elan). The trial in AD patients with agitation and aggression is a randomized, placebo-controlled study with approximately 400 patients that could potentially be used to support a marketing application for the indication. The Phase IIa trial in Down syndrome patients is a safety study, and data is expected in the third quarter of 2014. The reacquisition of the TT401 program by Eli Lilly gives Transition the flexibility to pursue additional early-stage candidates, and the Company is actively searching for new candidates to expand their overall pipeline.

In a 38 page Initiation Report by LifeSci Advisors, we explain Transition's unique business model and the progress of current development programs. We discuss the partnership with Eli Lilly for TT401, as well as the market potential for the product. We also detail Transition's wholly-owned ELND005 development programs, the market potential, and possible path to market for the treatment of agitation and aggression in Alzheimer's patients and also Down syndrome.

Dr. McDonald's full Initiation Report is available to download at no cost at the LifeSci Advisors website, www.lifesciadvisors.com. In addition to this Initiation Report, LifeSci Advisors will also provide ongoing coverage and event-based research updates on the Company as developments occur.

The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.

About LifeSci Advisors:
LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website, www.lifesciadvisors.com.

Important Disclosures:
The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has been compensated by the company that is the subject of the report described and future research reports, investor relations services, and general consulting services. Please read each report's full disclosures and analyst background on the LSA website, www.lifesciadvisors.com, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.

Forward-looking statements:
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.


Media Contact:
Andrew McDonald
Phone: (646) 597-6987
Email: andrew@lifesciadvisors.com


Transition Therapeutics Contact:
Dr. Tony Cruz
Chief Executive Officer
Phone: (416) 260-7770, x.223
Email: tcruz@transitiontherapeutics.com




Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES